Arcutis Biotherapeutics gets ZORYVE FDA approval for seborrheic dermatitis

Arcutis Biotherapeutics, Inc., a pioneer in immuno-dermatology, has announced the U.S. Food and Drug Administration's (FDA) approval of their new drug application for ZORYVE (roflumilast) ... Read More